Lead Product(s): TR009
Therapeutic Area: Oncology Product Name: ABL001
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: $117.0 million Upfront Cash: $7.0 million
Deal Type: Collaboration January 20, 2021
Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territory.